128577-48-0

Basic information

• Product Name: METHYL-2-BROMO-4-BROMOMETHYLBENZOATE
• Synonyms: Methyl 2-bromo-4-(bromomethyl);METHYL-2-BROMO-4-BROMOMETHYLBENZOATE
• CAS NO: 128577-48-0
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.97
• EINECS: 1312995-182-4
• Mol File: 128577-48-0.mol

Chemical Properties

• Boiling Point: 340.255 °C at 760 mmHg
• Flash Point: 159.581 °C
• Appearance: /
• Density: 1.78 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Ethyl Acetate (Soluble)
• Stability: Hygroscopic, Moisture Sensitive
• CAS DataBase Reference: METHYL-2-BROMO-4-BROMOMETHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-2-BROMO-4-BROMOMETHYLBENZOATE(128577-48-0)
• EPA Substance Registry System: METHYL-2-BROMO-4-BROMOMETHYLBENZOATE(128577-48-0)

Safety Data

• Hazardous Substances Data: 128577-48-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL-2-BROMO-4-BROMOMETHYLBENZOATE is used as a key intermediate in the synthesis of various pharmaceuticals. Its bromine atoms facilitate specific chemical reactions that are crucial for the production of certain drugs, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL-2-BROMO-4-BROMOMETHYLBENZOATE serves as an essential component in the creation of agrochemicals. Its properties allow for the synthesis of compounds that can be used in pest control and crop protection, enhancing agricultural productivity.
Used in Dye and Pigment Production:
METHYL-2-BROMO-4-BROMOMETHYLBENZOATE is utilized as an intermediate in the production of dyes and pigments. Its bromine content plays a significant role in the color development and stability of these compounds, making it indispensable in the colorants industry.
Used in Organic Synthesis:
As a versatile organic compound, METHYL-2-BROMO-4-BROMOMETHYLBENZOATE is employed in various organic synthesis processes. Its reactivity with other chemicals allows for the formation of a wide range of compounds, expanding the horizons of organic chemistry.
Used as a Precursor to Other Brominated Compounds:
Due to its bromine atoms, METHYL-2-BROMO-4-BROMOMETHYLBENZOATE is used as a precursor to other brominated compounds. It serves as a starting material for the synthesis of various brominated chemicals, which have applications in different industries such as flame retardants and specialty chemicals.

InChI:InChI=1/C9H8Br2O2/c1-13-9(12)7-3-2-6(5-10)4-8(7)11/h2-4H,5H2,1H3

Upstream product

• 7697-27-0 2-bromo-4-methylbenzoic acid 
• 87808-49-9 2-bromo-4-methyl-benzoic acid methyl ester 

Downstream Products

• 133052-53-6 methyl 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-2-bromobenzoate 
• 84542-11-0 2-(4-formylphenyl)-2-methylpropionic acid methyl ester 
• 87808-18-2 2-bromo-4-(4-acetyl-3-hydroxy-2-propylphenoxy)methylbenzoic acid 
• 133052-88-7 2-Bromo-4-(2-butyl-benzoimidazol-1-ylmethyl)-benzoic acid 
• 1252572-71-6 methyl 2-bromo-4-(cyanomethyl)benzoate 
• 1070870-67-5 methyl 2-bromo-4-[(methylamino)methyl]benzoate 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

A hit deconstruction approach for the discovery of fetal hemoglobin inducers

Beta-hemoglobinopathies such as sickle cell disease represent a major global unmet medical need. De-repression of fetal hemoglobin in erythrocytes is a clinically validated approach for the management of sickle cell disease, but the only FDA-approved medicine for this purpose has limitations to its use. We conducted a phenotypic screen in human erythroid progenitor cells to identify molecules with the ability to de-repress fetal hemoglobin, which resulted in the identification of the benzoxaborole-containing hit compound 1. This compound was found to have modest cellular potency and lead-like pharmacokinetics, but no identifiable SAR to enable optimization. Systematic deconstruction of a closely related analog of 1 revealed the fragment-like carboxylic acid 12, which was then optimized to provide tetrazole 31, which had approximately 100-fold improved cellular potency compared to 1, high levels of oral exposure in rats, and excellent solubility.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated

Mild Benzylic Monobromination of Methyl Toluates in Aqueous CTAB

A strategy has been developed for the regioselective monobromination of methyl toluates by using tert-butylhydrogen peroxide and potassium bromide (TBHP/KBr) in a cetyltrimethylammonium bromide (CTAB) micellar medium. Ultrasonic and microwave-assisted protocols recorded increased rates and product yields under mild reaction conditions, coupled with a straightforward isolation procedure.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

FXR AGONISTS

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

Substituted aryloximes

The present invention relates to substituted aryl oximes and methods of using them.

Benz[4,5]imidazole-containing angiotensin antagonists

The invention concerns novel heterocyclic compounds of the formula I as defined herein and their physiologically acceptable salts, together with pharmaceutical compositions containing them. The heterocyclic compounds antagonize the actions of angiotensin II and are of value in treating diseases or medical conditions such as hypertension and congestive heart failure in warm-blooded animals. The invention further includes processes for the manufacture of the novel compounds and their use in medical treatment.